Foot-and-mouth disease virus-like particles produced by a SUMO fusion protein system in Escherichia coli induce potent protective immune responses in guinea pigs, swine and cattle

Veterinary Research

Volumn 44, Issue 1, 2013, Pages

  Guo, Hui Chen ^a   Sun, Shi Qi ^a   Jin, Ye ^a   Yang, Shun Li ^a   Wei, Yan Quan ^a   Sun, De Hui ^a   Yin, Shuang Hui ^a   Ma, Jun Wu ^a   Liu, Zai Xin ^a   Guo, Jian Hong ^a   Luo, Jian Xun ^a   Yin, Hong ^a   Liu, Xiang Tao ^a   Liu, Ding Xiang ^a,b  

^a INSTITUTE OF PLANT PROTECTION   (China)

^b NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALIA; BOS; CAVIA; ESCHERICHIA COLI; FOOT-AND-MOUTH DISEASE VIRUS; MIRIDAE; PROKARYOTA; SUIDAE;

CAPSID PROTEIN; ESCHERICHIA COLI PROTEIN; SUMO 1 PROTEIN; VIRUS LIKE PARTICLE VACCINE; VIRUS VACCINE;

ANIMAL; BOVINAE; CONTROLLED STUDY; ESCHERICHIA COLI; FOOT AND MOUTH DISEASE; FOOT AND MOUTH DISEASE VIRUS; GUINEA PIG; IMMUNOLOGY; METABOLISM; RANDOMIZED CONTROLLED TRIAL; SWINE; VIROLOGY; ARTICLE; CATTLE; CONTROLLED CLINICAL TRIAL;

ANIMALS; CAPSID PROTEINS; CATTLE; ESCHERICHIA COLI; ESCHERICHIA COLI PROTEINS; FOOT-AND-MOUTH DISEASE; FOOT-AND-MOUTH DISEASE VIRUS; GUINEA PIGS; SUMO-1 PROTEIN; SWINE; VACCINES, VIRUS-LIKE PARTICLE; VIRAL VACCINES;

EID: 84879815475     PISSN: 09284249     EISSN: 12979716     Source Type: Journal    
DOI: 10.1186/1297-9716-44-48     Document Type: Article

References (61)

1. Foot-and-mouth disease: host range and pathogenesis. Alexandersen S, Mowat N, Curr Top Microbiol Immunol 2005 288 9 42 10.1007/3-540-27109-0-2 15648173 (Pubitemid 39657077)
2. Molecular aspects of foot-and-mouth disease virus virulence and host range: role of host cell receptors and viral factors. Baxt B, Rieder E, Foot and mouth disease: current perspectives Norfolk: Horizon Bioscience, Sobrino F, Domingo E, 2004 145 172
3. Epidemiological characteristics and financial costs of the 1997 foot-and-mouth disease epidemic in Taiwan. Yang PC, Chu RM, Chung WB, Sung HT, Vet Rec 1999 145 731 734 10972111 (Pubitemid 30009285)
4. Clinical and laboratory investigations of five outbreaks of foot-and-mouth disease during the 2001 epidemic in the United Kingdom. Alexandersen S, Kitching RP, Mansley LM, Donaldson AI, Vet Rec 2003 152 489 496 10.1136/vr.152.16.489 12733557 (Pubitemid 36546951)
5. Economic costs of the foot and mouth disease outbreak in the United Kingdom in 2001. Thompson D, Muriel P, Russell D, Osborne P, Bromley A, Rowland M, Creigh-Tyte S, Brown C, Rev Sci Tech 2002 21 675 687 12523706 (Pubitemid 36080133)
6. Foot-and-mouth disease. Grubman MJ, Baxt B, Clin Microbiol Rev 2004 17 465 493 10.1128/CMR.17.2.465-493.2004 15084510 (Pubitemid 38534037)
7. Control and eradication of foot-and-mouth disease. Sutmoller P, Barteling SS, Olascoaga RC, Sumption KJ, Virus Res 2003 91 101 144 10.1016/S0168-1702(02) 00262-9 12527440 (Pubitemid 36082879)
8. The coming of age of virus-like particle vaccines. Jennings GT, Bachmann MF, Biol Chem 2008 389 521 536 18953718 (Pubitemid 351874198)
9. Structures of virus and virus-like particles. Johnson JE, Chiu W, Curr Opin Struct Biol 2000 10 229 235 10.1016/S0959-440X(00)00073-7 10753814 (Pubitemid 30198951)
10. Virus-like particles: passport to immune recognition. Grgacic EVL, Anderson DA, Methods 2006 40 60 65 10.1016/j.ymeth.2006.07.018 16997714 (Pubitemid 44415499)
11. Expression of foot-and-mouth disease virus capsid proteins in silkworm-baculovirus expression system and its utilization as a subunit vaccine. Li Z, Yi Y, Yin X, Zhang Z, Liu J, PLoS One 2008 3 2273 10.1371/journal.pone. 0002273 18509464
12. Synthesis of empty capsid-like particles of Asia I foot-and-mouth disease virus in insect cells and their immunogenicity in guinea pigs. Cao Y, Lu Z, Sun J, Bai X, Sun P, Bao H, Chen Y, Guo J, Li D, Liu X, Liu Z, Vet Microbiol 2009 137 10 17 10.1016/j.vetmic.2008.12.007 19167843
13. Development of foot-and-mouth disease virus (FMDV) serotype O virus-like-particles (VLPs) vaccine and evaluation of its potency. Mohana Subramanian B, Madhanmohan M, Sriraman R, Chandrasekhar Reddy RV, Yuvaraj S, Manikumar K, Rajalakshmi S, Nagendrakumar SB, Rana SK, Srinivasan VA, Antiviral Res 2012 96 288 295 10.1016/j.antiviral.2012.09.019 23043941
14. Development of a foot-and-mouth disease virus serotype A empty capsid subunit vaccine using silkworm (Bombyx mori) pupae. Li Z, Yi Y, Yin X, Zhang Y, Liu M, Liu H, Li X, Li Y, Zhang Z, Liu J, PLoS One 2012 7 43849 10.1371/journal.pone.0043849 22952788
15. FMD subunit vaccine produced using a silkworm-baculovirus expression system: protective efficacy against two type Asia1 isolates in cattle. Li Z, Yin X, Yi Y, Li X, Li B, Lan X, Zhang Z, Liu J, Vet Microbiol 2011 149 99 103 10.1016/j.vetmic.2010.10.022 21109368
16. Development of novel strategies to control foot-and-mouth disease: marker vaccines and antivirals. Grubman MJ, Biologicals 2005 33 227 234 10.1016/j.biologicals.2005.08.009 16289996 (Pubitemid 41743812)
17. Protection of guinea pigs and swine by a recombinant adenovirus expressing O serotype of foot-and-mouth disease virus whole capsid and 3C protease. Lu Z, Bao H, Cao Y, Sun P, Guo J, Li P, Bai X, Chen Y, Xie B, Li D, Liu Z, Xie Q, Vaccine 2008 26 Suppl 6 48 G53 19178894
18. Early protection against homologous challenge after a single dose of replication-defective human adenovirus type 5 expressing capsid proteins of foot-and-mouth disease virus (FMDV) strain A24. Moraes MP, Mayr GA, Mason PW, Grubman MJ, Vaccine 2002 20 1631 1639 10.1016/S0264-410X(01)00483-2 11858872 (Pubitemid 34169805)
19. Rapid protection of cattle from direct challenge with foot-and-mouth disease virus (FMDV) by a single inoculation with an adenovirus-vectored FMDV subunit vaccine. Pacheco JM, Brum MC, Moraes MP, Golde WT, Grubman MJ, Virology 2005 337 205 209 10.1016/j.virol.2005.04.014 15893355 (Pubitemid 40798988)
20. Adenovirus serotype 5 vectored foot-and-mouth disease subunit vaccines: the first decade. Grubman MJ, Moraes MP, Neilan J, Ettyreddy D, Butman BT, Brough DE, Brake DA, Future Virol 2010 5 51 64 10.2217/fvl.09.68
21. Production of FMDV virus-like particles by a SUMO fusion protein approach in Escherichia coli. Lee CD, Yan YP, Liang SM, Wang TF, J Biomed Sci 2009 16 69 10.1186/1423-0127-16-69 19671144
22. Rapid protein-folding assay using green fluorescent protein. Waldo GS, Standish BM, Berendzen J, Terwilliger TC, Nat Biotechnol 1999 17 691 695 10.1038/10904 10404163 (Pubitemid 29316148)
23. Use of bacteriophage T7 RNA polymerase to direct selective high-level expression of cloned genes. Studier FW, Moffatt BA, J Mol Biol 1986 189 113 130 10.1016/0022-2836(86)90385-2 3537305
24. Co-overexpression of folding modulators improves the solubility of the recombinant guinea pig liver transglutaminase expressed in Escherichia coli. Ikura K, Kokubu T, Natsuka S, Ichikawa A, Adachi M, Nishihara K, Yanagi H, Utsumi S, Prep Biochem Biotechnol 2002 32 189 205 10.1081/PB-120004130 12071648 (Pubitemid 34629977)
25. Affinity fusion strategies for detection, purification, and immobilization of recombinant proteins. Nilsson J, Stahl S, Lundeberg J, Uhlen M, Nygren PA, Protein Expr Purif 1997 11 1 16 10.1006/prep.1997.0767 9325133 (Pubitemid 27434126)
26. An efficient system for high-level expression and easy purification of authentic recombinant proteins. Catanzariti AM, Soboleva TA, Jans DA, Board PG, Baker RT, Protein Sci 2004 13 1331 1339 10.1110/ps.04618904 15096636 (Pubitemid 38526098)
27. The solubility and stability of recombinant proteins are increased by their fusion to NusA. De Marco V, Stier G, Blandin S, De Marco A, Biochem Biophys Res Commun 2004 322 766 771 10.1016/j.bbrc.2004.07.189 15336530 (Pubitemid 39164419)
28. Expression and purification of the first nucleotide-binding domain and linker region of human multidrug resistance gene product: comparison of fusions to glutathione S-transferase, thioredoxin and maltose binding protein. Wang C, Castro AF, Wilkes DM, Altenberg GA, Biochem J 1999 338 77 81 10.1042/0264-6021:3380077 9931301 (Pubitemid 29097288)
29. High-level expression of soluble protein in Escherichia coli using a His6-tag and maltose-binding-protein double-affinity fusion system. Pryor KD, Leiting B, Protein Expr Purif 1997 10 309 319 10.1006/prep.1997.0759 9268677 (Pubitemid 27354171)
30. SUMO fusions and SUMO-specific protease for efficient expression and purification of proteins. Malakhov MP, Mattern MR, Malakhova OA, Drinker M, Weeks SD, Butt TR, J Struct Funct Genomics 2004 5 75 86 15263846 (Pubitemid 39030623)
31. Assembly of foot-and-mouth-disease virus empty capsids synthesized by a vaccinia virus expression system. Abrams CC, King AMQ, Belsham GJ, J Gen Virol 1995 76 3089 3098 10.1099/0022-1317-76-12-3089 8847514 (Pubitemid 26003118)
32. Specificity of enzyme-substrate interactions in foot-and-mouth disease virus polyprotein processing. Ryan MD, Belsham GJ, King AMQ, Virology 1989 173 35 45 10.1016/0042-6822(89)90219-5 2554577 (Pubitemid 19268249)
33. Intracellular expression and processing of foot-and-mouth disease virus capsid precursors using vaccinia virus vectors influence of the l protease. Belsham GJ, Brangwyn JK, Ryan MD, Abrams CC, King AMQ, Virology 1990 176 524 530 10.1016/0042-6822(90)90022-J 2161149 (Pubitemid 20177042)
34. Formation of virus-like particles from O-type foot-and-mouth disease virus in insect cells using codon-optimized synthetic genes. Cao Y, Sun P, Fu Y, Bai X, Tian F, Liu X, Lu Z, Liu Z, Biotechnol Lett 2010 32 1223 1229 10.1007/s10529-010-0295-8 20464450
35. Self-assembly of virus-like particles of porcine circovirus type 2 capsid protein expressed from Escherichia coli. Yin S, Sun S, Yang S, Shang Y, Cai X, Liu X, Virol J 2010 7 166 10.1186/1743-422X-7-166 20646322
36. Immune response in guinea pigs vaccinated with DNA vaccine of foot-and-mouth disease virus O/China99. Guo H, Liu Z, Sun S, Bao H, Chen Y, Liu X, Xie Q, Vaccine 2005 23 3236 3242 10.1016/j.vaccine.2004.03.074 15837227 (Pubitemid 40523115)
37. The effect of bovine IFN-γ on the immune response in guinea pigs vaccinated with DNA vaccine of foot-and-mouth disease virus. Guo HC, Liu ZX, Sun SQ, Leng QW, Li D, Liu XT, Xie QG, Acta Biochim Biophys Sin (Shanghai) 2004 36 701 706 10.1093/abbs/36.10.701 (Pubitemid 39611004)
38. Immune potential of a novel multiple-epitope vaccine to FMDV type Asia 1 in guinea pigs and sheep. Shao JJ, Wang JF, Chang HY, Liu JX, Virol Sin 2011 26 190 197 10.1007/s12250-011-3174-0 21667339
39. Evaluation of automated RT-PCR to accelerate the laboratory diagnosis of foot-and-mouth disease virus. Reid SM, Grierson SS, Ferris NP, Hutchings GH, Alexandersen S, J Virol Methods 2003 107 129 139 10.1016/S0166-0934(02)00210-0 12505626 (Pubitemid 36005497)
40. New vaccine design based on defective genomes that combines features of attenuated and inactivated vaccines. Rodriguez-Calvo T, Ojosnegros S, Sanz-Ramos M, Garcia-Arriaza J, Escarmis C, Domingo E, Sevilla N, PLoS One 2010 5 10414 10.1371/journal.pone.0010414 20454676
41. Amino-acid substitutions in the poliovirus maturation cleavage site affect assembly and result in accumulation of provirions. Ansardi DC, Morrow CD, J Virol 1995 69 1540 1547 7853487
42. Role of maturation cleavage in infectivity of picornaviruses: activation of an infectosome. Lee WM, Monroe SS, Rueckert RR, J Virol 1993 67 2110 2122 8383233 (Pubitemid 23088386)
43. Role and mechanism of the maturation cleavage of VP0 in poliovirus assembly: structure of the empty capsid assembly intermediate at 2.9 A resolution. Basavappa R, Syed R, Flore O, Icenogle JP, Filman DJ, Hogle JM, Protein Sci 1994 3 1651 1669 10.1002/pro.5560031005 7849583 (Pubitemid 24356589)
44. Poliovirus mutants at histidine 195 of VP2 do not cleave VP0 into VP2 and VP4. Hindiyeh M, Li Q-H, Basavappa R, Hogle JM, Chow M, J Virol 1999 73 9072 9079 10516013 (Pubitemid 29487060)
45. Characterization of synthetic foot-and-mouth disease virus provirions separates acid-mediated disassembly from infectivity. Knipe T, Rieder E, Baxt B, Ward G, Mason PW, J Virol 1997 71 2851 2856 9060641 (Pubitemid 27119925)
46. In-vitro assembly of poliovirus 14 s subunits identification of the assembly promoting activity of infected cell extracts. Rombaut B, Foriers A, Boeye A, Virology 1991 180 781 787 10.1016/0042-6822(91)90091-O 1846498
47. Dissecting the roles of VP0 cleavage and RNA packaging in picornavirus capsid stabilization: the structure of empty capsids of foot-and-mouth disease virus. Curry S, Fry E, Blakemore W, Abu-Ghazaleh R, Jackson T, King A, Lea S, Newman J, Stuart D, J Virol 1997 71 9743 9752 9371640 (Pubitemid 27492423)
48. Stability and immunogenicity of empty particles of foot-and-mouth disease virus. Rweyemamu MM, Terry G, Pay TWF, Arch Virol 1979 59 69 79 10.1007/BF01317896 218538 (Pubitemid 9100534)
49. Experimental studies with foot-and-mouth disease virus type Asia-1, responsible for the 2005 epidemic in China. Zhang Q, Li D, Liu X, Liu Z, Cai X, Wu G, Qi S, Yang S, Yan X, Shang Y, He J, Ma J, Li J, Ma W, Han R, Liu X, Zhang J, Xie Q, Zhang Z, Res Vet Sci 2008 85 368 371 10.1016/j.rvsc.2007.11.005 18155114
50. World Organisation for Animal Health, Manual of diagnostic tests and vaccines for terrestrial animals Paris: World Organisation for Animal Health 2012
51. Neutralizing epitopes of type O foot-and-mouth disease virus. II. Mapping three conformational sites with synthetic peptide reagents. Parry NR, Barnett PV, Ouldridge EJ, Rowlands DJ, Brown F, J Gen Virol 1989 70 1493 1503 10.1099/0022-1317-70-6-1493 2471812 (Pubitemid 19165610)
52. Neutralizing epitopes of type O foot-and-mouth disease virus. I. Identification and characterization of three functionally independent, conformational sites. Barnett PV, Ouldridge EJ, Rowlands DJ, Brown F, Parry NR, J Gen Virol 1989 70 1483 1491 10.1099/0022-1317-70-6-1483 2471811 (Pubitemid 19165609)
53. Neutralization antigenic sites on type Asia-1 foot-and-mouth disease virus defined by monoclonal antibody-resistant variants. Butchaiah G, Morgan DO, Virus Res 1997 52 183 194 10.1016/S0168-1702(97)00117-2 9495534 (Pubitemid 28044209)
54. A new enzyme-linked immunosorbent assay (ELISA) for the detection of antibodies against foot-and-mouth disease virus. II. Application. Hamblin C, Barnett ITR, Crowther JR, J Immunol Methods 1986 93 123 129 10.1016/0022- 1759(86)90442-4 3021855 (Pubitemid 16005487)
55. A new enzyme-linked immunosorbent assay (ELISA) for the detection of antibodies against foot-and-mouth disease virus. I. Development and method of ELISA. Hamblin C, Burnett ITR, Hedger RS, J Immunol Methods 1986 93 115 121 10.1016/0022-1759(86)90441-2 3021854 (Pubitemid 16005486)
56. The relationship between serum antibody titres and protection from foot and mouth disease in pigs after oil emulsion vaccination. Black L, Francis MJ, Rweyemamu MM, Umehara O, Boge A, J Biol Stand 1984 12 379 389 10.1016/S0092-1157(84)80062-1 6098583 (Pubitemid 15119428)
57. Relationship between virus neutralization and serum protection bioassays for IgG and IgM antibodies to foot-and-mouth disease virus. Trautman R, Bennett CE, J Gen Virol 1979 42 457 466 10.1099/0022-1317-42-3-457 219135 (Pubitemid 9145460)
58. Protective immune responses against foot-and-mouth disease virus by vaccination with a DNA vaccine expressing virus-like particles. Jin HL, Xiao W, Xiao C, Yu Y, Kang YM, Du XG, Wei XF, Wang B, Viral Immunol 2007 20 429 440 10.1089/vim.2007.0031 17931113 (Pubitemid 47585320)
59. Protective immune response against foot-and-mouth disease. McCullough KC, De Simone F, Brocchi E, Capucci L, Crowther JR, Kihm U, J Virol 1992 66 1835 1840 1312607
60. Immunoregulation. O'Shea JJ, Nutman TB, eLS John Wiley & Sons, Ltd 2001
61. The effects of gamma interferon on replication of foot-and-mouth disease virus in persistently infected bovine cells. Zhang ZD, Hutching G, Kitching P, Alexandersen S, Arch Virol 2002 147 2157 2167 10.1007/s00705-002-0867-6 12417950 (Pubitemid 36003322)